• Caris Life Sciences Receives Tumor Profiling Industry’s First ISO 15189 Medical Laboratory Accreditation

    Irving, Tex., Dec. 19, 2013 — Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, has announced that its tumor profiling laboratory, located in Phoenix, Ariz., has obtained the molecular profiling industry’s first-ever accreditation to the International Standards Organization (ISO) 15189 “Medical laboratories – Requirements for quality and competence,” accredited by the American Association for Laboratory Accreditation (A2LA).  Caris’ laboratory performs the genomic testing associated with Caris Molecular Intelligence™, the company’s comprehensive tumor profiling service, … Read More

  • Caris Life Sciences Receives Patent for Molecular Profiling Service in The People’s Republic of China

    Latest Award Further Demonstrates Company’s Established International Intellectual Property Position Irving, Tex., Dec. 17, 2013 — Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, has been granted a patent in The People’s Republic of China covering its molecular profiling service, Caris Molecular Intelligence™, for cancer patients. China represents a large population of unmet medical need, with approximately 3.5 million people diagnosed with cancer each year, according to the nation’s National Cancer Registry, … Read More

  • 5,500-plus Breast Cancer Patient Tumor Profiling Study Suggests Potential Biomarker Targets in Therapy Selection for Triple Negative Breast Cancer (TNBC)

    Mutational status and protein analysis both key to better understanding possible treatment implications for difficult-to-treat disease Irving, Tex., Dec. 12, 2013 — Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, presented a breast cancer study at the 2013 CTCR-AACR San Antonio Breast Cancer Symposium held this week in San Antonio, Texas. The analysis focuses on identifying potentially actionable therapeutic targets and clinical strategies for triple negative breast cancer (TNBC), … Read More

  • Caris Life Sciences Presents Key Biomarker Data at 2013 Association for Molecular Pathology (AMP) Annual Meeting

    Findings further demonstrate the validity of a multiple-technology approach to tumor profiling for cancer patients Irving, Tex., Nov. 14, 2013 — Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present five tumor profiling studies at the 2013 Annual Meeting of the Association for Molecular Pathology (AMP), held this week in Phoenix, Ariz. Results were obtained using Caris’ comprehensive tumor profiling service, Molecular Intelligence™. Presentation highlights include: Comprehensive data on ERBB2 (HER2) mutation, … Read More

  • Caris Life Sciences Launches Significant Enhancements to Industry-leading Cancer Tumor Profiling Service

    Key components include an upgraded online physician portal, simplified genomic profile and newly-added biomarkers to support more informed therapeutic selections  Irving, Tex., Oct. 9, 2013 — Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, today launched significant enhancements to its Molecular Intelligence™ tumor profiling service. These enhancements include significant updates to MI Portal™, the company’s online physician resource, a streamlined molecular profiling panel structure and the addition of two biomarkers. … Read More